Start-up Epirus Biopharmaceuticals Inc.’s in-market, for-market approach to making and selling biosimilars in emerging territories could be just the “David” ticket to beat pharma Goliaths that dominate the realm, said Amit Munshi, president and CEO of the Boston-based firm.